Graves Ophthalmopathy Clinical Trial
Official title:
A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy
The purpose of this study is to investigate the safety and tolerability of otelixizumab in patients with Graves' ophthalmopathy (thyroid eye disease). There is currently no alternative therapy available for this condition other than treatment with steroids, or radiotherapy and surgery. The study also includes a comparison of the current steroid treatment, methylprednisolone, with the proposed new otelixizumab treatment.
This is a study of otelixizumab, a monoclonal antibody (MAb) directed against the human lymphocyte antigen CD3 (a protein found on a certain type of white blood cell). This will be an open-label, comparator-controlled, two part study to evaluate the safety and tolerability of otelixizumab in patients with Graves' ophthalmopathy (GO). It will also look to see if otelixizumab affects GO and how it works compared to methylprednisolone (the standard treatment for active GO). In Part A, between one and four groups of 5 patients will receive doses of otelixizumab administered over 8 days. The first dose level will provide a low cumulative dose, this low dose level has been safely administered in previous studies. Safety and clinical response data will be reviewed after 8 weeks, if no clinical response is seen and there are no safety concerns, the dose of otelixizumab will be increased and a new group of subjects will enter Part A. In subsequent groups cumulative medium low, medium high, and high doses of otelixizumab may be investigated. However if a clinical response is seen at the lowest dose the study will move directly to Part B. In Part B, patients will receive either otelixizumab at the dose set from Part A, over 8 days (5 patients) or methylprednisolone weekly for 12 weeks (5 patients). All dosing will be by intravenous infusion. All participants will undergo long term safety evaluation for 48 months. Key assessments include vital signs, 12-lead ECG, liver function tests, thyroid function, viral monitoring, monitoring of cortisol and ACTH levels, laboratory safety tests and adverse event (side effect) data. Assessment of GO severity will be evaluated using recommended assessments including clinical activity assessments and quality of life questionnaires. Measurements of exploratory biomarkers (proteins found naturally in the blood) are also included in this study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05532072 -
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
|
Early Phase 1 | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05678374 -
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
Recruiting |
NCT03708627 -
Bimatoprost as a Treatment for Graves' Orbitopathy
|
Early Phase 1 | |
Not yet recruiting |
NCT06413043 -
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy
|
N/A | |
Withdrawn |
NCT01379196 -
Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06275373 -
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
|
||
Recruiting |
NCT06226545 -
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
|
Phase 2 | |
Recruiting |
NCT05126147 -
Hydroxychloroquine in Mild Graves' Orbitopathy
|
Phase 4 | |
Recruiting |
NCT01999790 -
Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy
|
N/A | |
Recruiting |
NCT03066076 -
Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy
|
Phase 3 | |
Active, not recruiting |
NCT03122847 -
Glucocorticoids and Bone in Graves' Ophthalmopathy
|
||
Terminated |
NCT01893450 -
Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment
|
N/A | |
Completed |
NCT00348413 -
Thyroid Treatment Trial
|
N/A | |
Completed |
NCT03498417 -
Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
|
||
Not yet recruiting |
NCT04598815 -
Sirolimus for Graves' Orbitopathy (GO)
|
Phase 2 | |
Completed |
NCT05793359 -
Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy
|
||
Completed |
NCT05775185 -
Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
|
||
Recruiting |
NCT02203682 -
Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
|
Phase 2 |